Evidence map›Paper›PMID 38481819›Full record

ArticleInternational journal of biological sciences2024

Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma.

Bo Wang, Fang-Zheng Qi, Ping Chen, Luo-Meng Qian, Hui-Shan Su, Yang Wang, Chen-Hui Wang, Ya-Xin Hou, Qing Zhang, Ding Li and 2 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Lysophosphatidic acid-induced Arf6-driven macropinocytosis of CD147International journal of biological sciences · 2026
    Article
  3. Review
  4. Journal of the American Chemical Society · 2025
    Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Bo WangDepartment of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Fang-Zheng QiDepartment of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Ping ChenNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Luo-Meng QianDepartment of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Hui-Shan SuDepartment of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Yang WangDepartment of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Chen-Hui WangDepartment of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Ya-Xin HouDepartment of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Qing ZhangNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Ding LiNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Zhe-Sheng ChenDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, NY, 11439, USA.
Si-He ZhangDepartment of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Nankai University · CNTianjin Medical University Cancer Institute and Hospital · CNSt. John's University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNitroimidazolesPhosphoramide MustardsProdrugsAnimalsCell HypoxiaCell Line, TumorHumansHypoxiaMiceXenograft Model Antitumor AssaysNitroimidazolesPhosphoramide MustardsProdrugsTH 302Hepatocellular carcinomaHypoxia-activated antibodyOn-target off-tumor toxicityPKM2TH-302

Identifiers

PMID38481819
PMCPMC10929192
OpenAlexW4391984766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.